Clinical reference Biomarker Directory
Back to directory

IFNG

Emerging

IFN-gamma release underlies IGRA testing, now preferred over the tuberculin skin test for diagnosing latent TB.

Also known as IFN-gamma interferon gamma
In plain language

Interferon gamma is released by immune cells fighting TB infection, and measuring this response (rather than a traditional skin test) is now a preferred way to diagnose latent TB, especially in people who received the BCG vaccine as children.

Biomarker & context

Interferon gamma (IFN-γ) is a cytokine central to cell-mediated immune responses against intracellular pathogens, most notably Mycobacterium tuberculosis.

What it indicates

IFN-γ release in response to TB-specific antigens is the basis for interferon-gamma release assays (IGRAs), used to diagnose latent tuberculosis infection.

Diagnosis & clinical testing

IGRAs (e.g., QuantiFERON-TB) have become a preferred alternative to the traditional tuberculin skin test, since they aren't affected by prior BCG vaccination — a real practical advantage in vaccinated populations where skin tests can be falsely positive.

Guiding treatment

A positive IGRA in a patient without active TB symptoms supports latent TB treatment consideration (isoniazid or rifampin-based regimens) per current public health guidelines, without the false-positive risk that BCG vaccination creates for skin testing.

Clinical significance

Not affected by prior BCG vaccination, a key practical advantage over the traditional skin test.

References
  1. General infectious disease reference literature on interferon-gamma release assays (IGRAs) for latent tuberculosis diagnosis.